NO314533B1 - Anvendelse av toremifen eller et farmasöytisk akseptabelt salt derav for fremstilling av et medikament for behandling av systemisk lupuserytematodes - Google Patents
Anvendelse av toremifen eller et farmasöytisk akseptabelt salt derav for fremstilling av et medikament for behandling av systemisk lupuserytematodes Download PDFInfo
- Publication number
- NO314533B1 NO314533B1 NO19951596A NO951596A NO314533B1 NO 314533 B1 NO314533 B1 NO 314533B1 NO 19951596 A NO19951596 A NO 19951596A NO 951596 A NO951596 A NO 951596A NO 314533 B1 NO314533 B1 NO 314533B1
- Authority
- NO
- Norway
- Prior art keywords
- toremifene
- treatment
- lpr
- mice
- acceptable salt
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 10
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 title claims description 15
- 229960005026 toremifene Drugs 0.000 title claims description 14
- 201000000596 systemic lupus erythematosus Diseases 0.000 title claims description 10
- 239000003814 drug Substances 0.000 title claims description 8
- 238000004519 manufacturing process Methods 0.000 title claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract description 10
- 229940046836 anti-estrogen Drugs 0.000 abstract description 10
- 230000001833 anti-estrogenic effect Effects 0.000 abstract description 10
- 239000000328 estrogen antagonist Substances 0.000 abstract description 10
- 239000003862 glucocorticoid Substances 0.000 abstract description 8
- 238000002360 preparation method Methods 0.000 abstract description 8
- 241000699670 Mus sp. Species 0.000 description 28
- IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 22
- 229960004167 toremifene citrate Drugs 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 206010018364 Glomerulonephritis Diseases 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 230000003637 steroidlike Effects 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 229960005205 prednisolone Drugs 0.000 description 6
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 6
- 206010040628 Sialoadenitis Diseases 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 208000001050 sialadenitis Diseases 0.000 description 5
- 230000001363 autoimmune Effects 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 108010052621 fas Receptor Proteins 0.000 description 3
- 102000018823 fas Receptor Human genes 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010071155 Autoimmune arthritis Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 208000012761 aggressive behavior Diseases 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- SBVVUEPVKSOHHY-UHFFFAOYSA-N n,n-dimethyl-1-phenoxyethanamine Chemical compound CN(C)C(C)OC1=CC=CC=C1 SBVVUEPVKSOHHY-UHFFFAOYSA-N 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960003454 tamoxifen citrate Drugs 0.000 description 1
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP31077292 | 1992-10-27 | ||
| PCT/JP1993/001543 WO1994009764A1 (en) | 1992-10-27 | 1993-10-26 | Use of non steroidal anti estrogens for autoimmune diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO951596L NO951596L (no) | 1995-04-26 |
| NO951596D0 NO951596D0 (no) | 1995-04-26 |
| NO314533B1 true NO314533B1 (no) | 2003-04-07 |
Family
ID=18009292
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19951596A NO314533B1 (no) | 1992-10-27 | 1995-04-26 | Anvendelse av toremifen eller et farmasöytisk akseptabelt salt derav for fremstilling av et medikament for behandling av systemisk lupuserytematodes |
| NO20025179A NO317544B1 (no) | 1992-10-27 | 2002-10-28 | Produkter for autoimmune sykdommer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20025179A NO317544B1 (no) | 1992-10-27 | 2002-10-28 | Produkter for autoimmune sykdommer |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US6355688B1 (es) |
| EP (2) | EP0667768B1 (es) |
| KR (1) | KR100303634B1 (es) |
| CN (1) | CN1053337C (es) |
| AT (1) | ATE177008T1 (es) |
| AU (1) | AU5286693A (es) |
| DE (1) | DE69323759T2 (es) |
| DK (1) | DK0667768T3 (es) |
| ES (1) | ES2128441T3 (es) |
| GR (1) | GR3029682T3 (es) |
| NO (2) | NO314533B1 (es) |
| WO (1) | WO1994009764A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE406909T1 (de) * | 1993-05-13 | 2008-09-15 | Poniard Pharmaceuticals Inc | Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind |
| US5521198A (en) | 1993-12-21 | 1996-05-28 | Eli Lilly And Company | Methods of inhibiting autoimmune diseases |
| WO1998034583A2 (en) * | 1997-02-09 | 1998-08-13 | Pharmos Corporation | Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones |
| JP2002501624A (ja) | 1997-03-06 | 2002-01-15 | ナシュア コーポレイション | 偏光維持拡散シートを用いたディスプレイ |
| CA2380940C (en) * | 1999-08-13 | 2013-06-25 | Heinrich Wieland | Substances and agents for positively influencing collagen |
| US20020013327A1 (en) * | 2000-04-18 | 2002-01-31 | Lee Andrew G. | Compositions and methods for treating female sexual dysfunction |
| US7069444B2 (en) * | 2002-01-25 | 2006-06-27 | Brent A. Lowensohn | Portable wireless access to computer-based systems |
| US9040507B2 (en) * | 2008-06-02 | 2015-05-26 | Novelmed Therapeutics, Inc. | Method for treating inflammatory conditions |
| CN102307795B (zh) | 2009-02-09 | 2015-04-15 | 威士伯采购公司 | 在店内可调色的不吸收红外线的漆料和色料系统 |
| CN102307954B (zh) | 2009-02-09 | 2014-04-09 | 威士伯采购公司 | 在店内可调色的不吸收红外线的漆料和色料系统 |
| AU2011272751A1 (en) | 2010-07-01 | 2012-12-20 | Valspar Sourcing, Inc. | Infrared-reflective two-part coating composition |
| MX2013003965A (es) | 2010-10-20 | 2013-06-28 | Valspar Sourcing Inc | Sistemas de revestimiento a base de agua con resistencia mejorada al agua y al calor. |
| RU2572504C1 (ru) * | 2013-12-26 | 2016-01-10 | Андрей Константинович Иорданишвили | Способ лечения лучевой сиалоаденопатии |
| EP3420024A4 (en) | 2016-02-23 | 2020-02-19 | Advanced Environmental Recycling Technologies, Inc | COMPOSITIONS AND METHODS FOR REDUCING THE SURFACE TEMPERATURE OF COMPOSITE ITEMS |
| AU2018205039B2 (en) | 2017-01-01 | 2022-09-22 | Moistureshield, Inc. | Methods for coating composite articles |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU172948B (hu) | 1976-02-05 | 1979-01-28 | Gyogyszerkutato Intezet | Sposob poluchenija osnovnykh proizvodnykh trifenil-alkenov |
| EP0002097B1 (en) | 1977-08-22 | 1981-08-05 | Imperial Chemical Industries Plc | Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them |
| DE3046719C2 (de) | 1980-12-11 | 1983-02-17 | Klinge Pharma GmbH, 8000 München | 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel |
| FI67538C (fi) | 1982-05-27 | 1985-04-10 | Farmos Oy | Foerfarande foer framstaellning av (z)-1,2-difenyl-1-(4-(2-(n n-dimetylamino)etoxi)fenyl)-1-buten |
| GB2126576B (en) * | 1982-06-25 | 1985-06-19 | Farmos Group Limited | Alkane and alkene derivatives |
| US5348729A (en) * | 1988-11-30 | 1994-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | Evaluative means for detecting inflammatory reactivity |
| US4990538A (en) * | 1989-08-23 | 1991-02-05 | Harris Adrian L | Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs |
| JPH04312526A (ja) * | 1991-04-09 | 1992-11-04 | Fujisawa Pharmaceut Co Ltd | 骨疾患治療剤 |
-
1993
- 1993-10-26 KR KR1019930022299A patent/KR100303634B1/ko not_active IP Right Cessation
- 1993-10-26 ES ES93923058T patent/ES2128441T3/es not_active Expired - Lifetime
- 1993-10-26 EP EP93923058A patent/EP0667768B1/en not_active Expired - Lifetime
- 1993-10-26 EP EP96119031A patent/EP0776661A1/en not_active Withdrawn
- 1993-10-26 DK DK93923058T patent/DK0667768T3/da active
- 1993-10-26 AT AT93923058T patent/ATE177008T1/de not_active IP Right Cessation
- 1993-10-26 WO PCT/JP1993/001543 patent/WO1994009764A1/en active IP Right Grant
- 1993-10-26 DE DE69323759T patent/DE69323759T2/de not_active Expired - Fee Related
- 1993-10-26 AU AU52866/93A patent/AU5286693A/en not_active Abandoned
- 1993-10-27 CN CN93120398A patent/CN1053337C/zh not_active Expired - Fee Related
-
1995
- 1995-04-26 NO NO19951596A patent/NO314533B1/no unknown
-
1999
- 1999-03-12 GR GR990400766T patent/GR3029682T3/el unknown
-
2000
- 2000-03-01 US US09/516,435 patent/US6355688B1/en not_active Expired - Fee Related
-
2001
- 2001-07-16 US US09/906,169 patent/US6387958B1/en not_active Expired - Fee Related
-
2002
- 2002-01-10 US US10/044,064 patent/US6458848B1/en not_active Expired - Fee Related
- 2002-10-28 NO NO20025179A patent/NO317544B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO317544B1 (no) | 2004-11-08 |
| NO20025179L (no) | 1995-04-26 |
| GR3029682T3 (en) | 1999-06-30 |
| DE69323759T2 (de) | 1999-07-22 |
| EP0667768A1 (en) | 1995-08-23 |
| NO951596L (no) | 1995-04-26 |
| WO1994009764A1 (en) | 1994-05-11 |
| US6387958B1 (en) | 2002-05-14 |
| NO20025179D0 (no) | 2002-10-28 |
| US6355688B1 (en) | 2002-03-12 |
| EP0667768B1 (en) | 1999-03-03 |
| KR100303634B1 (ko) | 2001-11-22 |
| KR940008677A (ko) | 1994-05-16 |
| DE69323759D1 (de) | 1999-04-08 |
| CN1100930A (zh) | 1995-04-05 |
| AU5286693A (en) | 1994-05-24 |
| DK0667768T3 (da) | 1999-09-27 |
| US20020107231A1 (en) | 2002-08-08 |
| ATE177008T1 (de) | 1999-03-15 |
| CN1053337C (zh) | 2000-06-14 |
| US6458848B1 (en) | 2002-10-01 |
| EP0776661A1 (en) | 1997-06-04 |
| ES2128441T3 (es) | 1999-05-16 |
| NO951596D0 (no) | 1995-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO314533B1 (no) | Anvendelse av toremifen eller et farmasöytisk akseptabelt salt derav for fremstilling av et medikament for behandling av systemisk lupuserytematodes | |
| TWI389683B (zh) | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient | |
| JPH05507697A (ja) | 臓器移植拒絶反応の治療 | |
| CA2640484A1 (en) | Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith | |
| CN101677542B (zh) | 佛波醇酯的化合物及使用方法 | |
| JP2013521305A (ja) | ラキニモドを用いるループス関節炎の治療 | |
| CN1984654A (zh) | 抗－hiv逆转录酶和蛋白酶抑制剂的组合 | |
| Linton et al. | Methods of forced diuresis and its application in barbiturate poisoning | |
| Marigold et al. | Propranolol, oxprenolol, and sclerosing peritonitis. | |
| JP2017525719A (ja) | 関節リウマチの治療における１つの丸剤・錠剤・カプセル剤でのミノサイクリン、アシクログアノシン、アトルバスタチンおよびビタミンｄの使用 | |
| White et al. | Current and emerging strategies for the management of sarcoidosis | |
| US5886049A (en) | Remedy for autoimmune diseases | |
| RU2322238C2 (ru) | Лечение ревматоидного артрита | |
| CA2148006C (en) | Use of non-steroidal antiestrogens for autoimmune diseases | |
| JPS624229A (ja) | 鎮痛及び消炎作用を有する医薬 | |
| JP3566741B2 (ja) | 自己免疫疾患治療薬 | |
| WO2019004465A1 (ja) | ペマフィブラートを含有する医薬 | |
| JP2548223B2 (ja) | 腎臓疾患治療剤 | |
| WO2018206465A1 (en) | Method for treating multiple sclerosis using arsenic trioxide | |
| Ofili | Possibilities of the strong posterior wall of inguinal canal in women | |
| CN102614180A (zh) | 伊曲康唑在制备治疗多发性骨髓瘤药物中的应用 | |
| US20080319073A1 (en) | Colonic delivery therapeutic agents for inflammatory bowel disease | |
| CA2569479A1 (en) | Combination comprising a bcrp inhibitor and 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide | |
| WO2024172001A1 (ja) | 抗トリパノソーマ薬 | |
| Wakefield et al. | Investigation and management of scleritis |